C
Cadent Therapeutics
Cadent Therapeutics is a precision neuroscience company
About Cadent Therapeutics
Cadent Therapeutics is a biopharmaceutical company focused on developing first-in-class allosteric modulators to address unmet needs in central nervous system (CNS) disorders, including cognitive and movement disorders. The company leverages its extensive industry experience in medicinal chemistry, target selection, drug discovery, and drug optimization to advance a pipeline of novel allosteric modulators of ion channels. These ion channels, such as SK channels and NMDA receptors, are crucial for modulating neuronal communication and integration within the CNS. Cadent Therapeutics aims to positively modulate NMDA receptors to reverse hypofunction in schizophrenia patients and restore cognitive balance. Additionally, the company is developing positive allosteric modulators (PAMs) of SK channels to treat essential tremor (ET) and spinocerebellar ataxia (SCA). By targeting specific patient subsets based on genetics or other factors, Cadent Therapeutics strives to identify patients who will benefit most from their treatments, ensuring optimal efficacy with minimal side effects. The company operates in the biopharmaceutical market, serving patients with CNS disorders and generating revenue through the development and commercialization of its therapeutic candidates.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2020 | $770M | $770M | Novartis | — |
| SERIES BOther financing | Apr 2020 | $15M | $60M | Access Industries · Qiming Venture Partners · Cowen Group · Clal Biotechnology Industries | ↗ |
Growth signals
Latest recorded traffic for Cadent Therapeutics is 3.4K monthly website visits, up 353.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cadent Therapeutics in the Cambridge ecosystem
The Cadent Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Atlas Venture
Qiming Venture Partners
Cowen Group
Access Industries
Clal Biotechnology Industries
Other known investors1 additional known investor
Novartis
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cadent Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cadent Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








